Casirivimab/imdevimab vs placebo
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 3 [0.12, 73.43]1 study · 1505 participantsLow